ISSN: 2190-5991

Journal Home

Journal of Cachexia, Sarcopenia and Muscle Q1 Unclaimed

Wiley-Blackwell United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Journal of Cachexia, Sarcopenia and Muscle is a journal indexed in SJR in Physiology (medical) and Orthopedics and Sports Medicine with an H index of 88. It is an CC BY-NC-ND Journal with a Single blind Peer Review review system, and It has a price of 2250 €. The scope of the journal is focused on cachexia, sarcopenia, muscle, muscle wasting, wasting syndromes, body composition. It has an SJR impact factor of 2,159 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,159.

Type: Journal

Type of Copyright: CC BY-NC-ND

Languages: English

Open Access Policy: Open Access

Type of publications:

Publication frecuency: -

Categories: Orthopedics and Sports Medicine (Q1) Physiology (medical) (Q1)

Price

2250 €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Journal of Cachexia, Sarcopenia and Muscle

2,159

SJR Impact factor

88

H Index

264

Total Docs (Last Year)

443

Total Docs (3 years)

11851

Total Refs

4192

Total Cites (3 years)

395

Citable Docs (3 years)

8.23

Cites/Doc (2 years)

44.89

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Circulation Q1
Nature Metabolism Q1
Sleep Medicine Reviews Q1
Circulation: Arrhythmia and Electrophysiology Q1
JACC: Clinical Electrophysiology Q1

Compare this journals

Aims and Scope

Cachexia Sarcopenia Muscle Muscle wasting Wasting syndromes Body composition

Best articles by citations

A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project

Muscle mass measures and incident osteoporosis in a large cohort of postmenopausal women

Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer

Psoas

Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis

Psoas muscle fluorine-18-labelled fluoro-2-deoxy-d-glucose uptake associated with the incidence of existing and incipient metabolic derangement

Prevalence of sarcopenia among community-dwelling elderly of a medium-sized South American city: results of theCOMO VAI? study

Assessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibility

Increased desmin expression in hindlimb muscles of aging rats

Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer

Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!

Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia

SHOW MORE ARTICLES

Silver linings on the horizon: highlights from the 10th Cachexia Conference

Exercise restores muscle stem cell mobilization, regenerative capacity and muscle metabolic alterations via adiponectin/AdipoR1 activation in SAMP10 mice

Computed tomography diagnosed cachexia and sarcopenia in 725 oncology patients: is nutritional screening capturing hidden malnutrition?

Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration?

Trimetazidine restores the positive adaptation to exercise training by mitigating statin-induced skeletal muscle injury

Sources for skeletal muscle repair: from satellite cells to reprogramming

Febuxostat improves outcome in a rat model of cancer cachexia

The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia

Erratum to: Assessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibility

Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia

Degenerin channel activation causes caspase-mediated protein degradation and mitochondrial dysfunction in adultC.elegansmuscle

Tumour-specific and organ-specific protein synthesis rates in patients with pancreatic cancer